OrthoGraft is developing a biomaterial for bone regeneration consisting of collagen, hydroxyapatite, and natural occurring designer proteins that mediate biomineralization. The result is a self-assembled nano-orthobiologic that promises to limit the occurrences of non-unions in the spine and extremities through a novel stimulatory mechanism known as osteoinductive nanoarchitecture. Our FDA regulatory timeline projects penetration into the $4 billion bone substitute market 3 years following our seed funding round. We are currently raising a seed fund of $250k for our first animal trials.
Investor questions have not yet been answered for this business